Found: 61
Select item for more details and to access through your institution.
Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 11, p. 4567, doi. 10.1007/s00277-024-05984-6
- By:
- Publication type:
- Article
Like a bridge over troubled water: keeping the myeloma down en route to CAR-T.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01049-z
- By:
- Publication type:
- Article
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00912-9
- By:
- Publication type:
- Article
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00934-x
- By:
- Publication type:
- Article
Editorial: T-cell directed therapies in multiple myeloma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1206475
- By:
- Publication type:
- Article
'X' marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma.
- Published in:
- British Journal of Haematology, 2024, v. 205, n. 2, p. 416, doi. 10.1111/bjh.19640
- By:
- Publication type:
- Article
T‐cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma: When the cure fails!
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 3, p. 753, doi. 10.1111/bjh.19267
- By:
- Publication type:
- Article
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 3, p. 440, doi. 10.1111/bjh.14429
- By:
- Publication type:
- Article
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 1, p. 52, doi. 10.1111/bjh.13517
- By:
- Publication type:
- Article
Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 2, p. 395, doi. 10.1177/1078155221995532
- By:
- Publication type:
- Article
Minimization of Organocuprate Complexity through Self-Organization: Remarkable Orientation Effect in Mixed Cuprate π Complexes.
- Published in:
- Angewandte Chemie, 2012, v. 124, n. 11, p. 2735, doi. 10.1002/ange.201107060
- By:
- Publication type:
- Article
Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1411, doi. 10.1002/ajh.27314
- By:
- Publication type:
- Article
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta‐analysis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 6, p. 1056, doi. 10.1002/ajh.27288
- By:
- Publication type:
- Article
Soluble B‐cell maturation antigen in multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 727, doi. 10.1002/ajh.27225
- By:
- Publication type:
- Article
Trial designs and endpoints for immune therapies in multiple myeloma.
- Published in:
- American Journal of Hematology, 2023, v. 98, p. S35, doi. 10.1002/ajh.26753
- By:
- Publication type:
- Article
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 2, p. E54, doi. 10.1002/ajh.26420
- By:
- Publication type:
- Article
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 11, p. E430, doi. 10.1002/ajh.26333
- By:
- Publication type:
- Article
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.02616
- By:
- Publication type:
- Article
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 349
- By:
- Publication type:
- Article
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
- Published in:
- Oncology (08909091), 2024, v. 38, n. 6, p. 239, doi. 10.46883/2024.25921023
- By:
- Publication type:
- Article
Atypical IgG4+ Plasmacytic Proliferations and Lymphomas: Characterization of 11 Cases.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 7, p. 8005, doi. 10.1002/cam4.5584
- By:
- Publication type:
- Article
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams.
- Published in:
- Frontiers in Oncology, 2022, v. 11, p. 1, doi. 10.3389/fonc.2021.819127
- By:
- Publication type:
- Article
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/2040620721989585
- By:
- Publication type:
- Article
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/2040620720987075
- By:
- Publication type:
- Article
Selinexor in relapsed/refractory multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2020, v. 11, p. 1, doi. 10.1177/2040620720930629
- By:
- Publication type:
- Article
Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2014, v. 14, n. 1, p. e39, doi. 10.1016/j.clml.2013.09.012
- By:
- Publication type:
- Article
Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 8, p. 553, doi. 10.1016/j.clml.2024.04.002
- By:
- Publication type:
- Article
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 6, p. 350, doi. 10.1016/j.clml.2024.03.005
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Pathology and Pathogenesis of Nodal Peripheral T-Cell Lymphomas.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 5, p. 287, doi. 10.1016/j.clml.2021.10.006
- By:
- Publication type:
- Article
The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 3, p. 192, doi. 10.1016/j.clml.2021.09.015
- By:
- Publication type:
- Article
Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 2, p. 129, doi. 10.1016/j.clml.2021.09.004
- By:
- Publication type:
- Article
Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 11, p. 752, doi. 10.1016/j.clml.2021.06.020
- By:
- Publication type:
- Article
NS-64: Lessons learned: patient management and outcomes of Multiple Myeloma patients during the COVID-19 pandemic in New York City.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S167, doi. 10.1016/S2152-2650(21)02358-2
- By:
- Publication type:
- Article
P-213: A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S156, doi. 10.1016/S2152-2650(21)02340-5
- By:
- Publication type:
- Article
P-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S142, doi. 10.1016/S2152-2650(21)02318-1
- By:
- Publication type:
- Article
P-063: Pathogenic germline variants in hereditary cancer genes in patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S73, doi. 10.1016/S2152-2650(21)02197-2
- By:
- Publication type:
- Article
OAB-053: Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S38, doi. 10.1016/S2152-2650(21)02133-9
- By:
- Publication type:
- Article
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 5, p. e470, doi. 10.1016/j.clml.2020.12.026
- By:
- Publication type:
- Article
Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e118, doi. 10.1016/j.clml.2019.09.196
- By:
- Publication type:
- Article
Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e117, doi. 10.1016/j.clml.2019.09.195
- By:
- Publication type:
- Article
Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Incidence and Timing of Graft Versus Host Disease (GVHD) After Daratumumab(Dara) Anti CD38 Therapy Post Allogeneic Transplant (alloHCT)for Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e71, doi. 10.1016/j.clml.2017.03.129
- By:
- Publication type:
- Article